证券代码：688458 证券简称：美芯晟 公告编号：2026-007 美芯晟科技（北京）股份有限公司 第二届董事会第八次会议决议公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗漏，并对其内容 的真实性、准确性和完整性承担法律责任。 一、董事会会议召开情况 美芯晟科技（北京）股份有限公司（以下简称"公司"）第二届董事会第八次会议的会议通知于2026年1 月26日以邮件形式发出，并于2026年1月27日在公司会议室以现场会议和线上通讯会议同时进行的方式 召开。会议应出席董事7人，实际出席会议董事7人，全体董事均出席会议。 会议由董事长程宝洪先生（Mr. CHENG BAOHONG）召集并主持，会议召集和召开程序符合《公司 法》等相关法律法规和公司章程规定。表决形成的决议合法、有效。 二、董事会会议审议情况 会议认真审议了提交会议审议的议案，经投票表决，会议通过了以下议案，决议如下： （一）审议通过《关于以股权收购及增资方式取得上海鑫雁微电子股份有限公司100%股权的议案》 公司拟使用自有资金以股权收购及增资方式取得上海鑫雁微电子股份有限公司100%股权，本次交易金 额合计为人民币 ...

Group 1 - The resilience of technology stocks continues to attract investors, with the A-share market showing strong performance and indices reaching new highs [1] - The current market liquidity is abundant, and thematic trends are expected to continue, with a focus on sectors like commercial aerospace, satellite connectivity, smart driving, and brain-computer interfaces [1] - The "spring rally" is anticipated to be more stable and prolonged compared to previous years, with attention on capital inflows and outflows in January [1] Group 2 - There are 14 stocks with a market capitalization below 5 billion yuan, a research and development expenditure ratio exceeding 10%, and a price drop of over 20% since their peak in 2025 [2] - Among these, Iron Big Technology has the lowest market cap at under 2 billion yuan, focusing on railway signal and communication equipment [2] - Mengke Pharmaceuticals leads in R&D intensity with a ratio of nearly 174%, specializing in small molecule drug development for infectious diseases [2] Group 3 - Companies like Ruina Intelligent, Meixin Sheng, and Biyiwei have R&D expenditure ratios exceeding 20% in the first half of 2025 [3] - Institutions are particularly interested in Kangnong Agriculture, with other companies like Minxin Co., Vision Intelligent, and Meixin Sheng also receiving attention [3] - Minxin Co. is recognized for its MEMS chip design and manufacturing capabilities, indicating a balanced development in its product revenue structure [3]